- Email: [email protected]
The use of norgestomet implants and FSH for estrus synchonization and superovulation in goats
THERIOGENOLOGY
THE USE OF NORGESTOMET IMPLANTS AND FSH FOR ESTRUS SYNCHRONIZATION AND SUPEROVULATION IN GOATS R. J. Pendletonl, C. R. Youngsl, R. W. Roriel, M. A. Memon2 and R. A. Godkel 'Animal Science Department, LAES, LSU Agricultural Center 2Department of Veterinary Clinical Sciences, LSU School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803
The objective of this study was to assess the feasibilit of using norgestomet ear implants and follicle stimulating hormone rFSH) in a caprine embryo transfer program. In late June, ten crossbred dairy goats of varying ages were implagted with a standard bovine 6 mg norgestomet ear implant (Syncromate-B , CEVA Laboratories, Inc.) for 16 to 17 days. Implants were replaced with new implants after 10 days to insure an adequate progestagen treatment. Superovulation was induced by twice dail,y injections of descending doses of 4, 3, 2 and 1 mg of FSH (FSH-P :Burns-Biotec) starting 2 days prior to implant removal. Similarly, control does (n=lO) were administered saline (as a placebo) and were checked for signs of estrus with a vasectomized male along with the treated does. Starting at the onset of estrus, all treated does were naturally mated to several males each morning and evening until the end of estrus. After implant removal, 6 of 10 treated animals exhibited estrus within 24 hours and 9 of 10 within 48 hours. The remaining doe which failed to show estrus had exudate around the implant which likely impaired its effectiveness. Two of the control does exhibited estrus during the estrus detection period. Embryos were surgically collected on days 5 to 6 of the estrous cycle (day 0 = onset of estrus), and control does were laparoscopically examined at that time to evaluate ovarian activity. The FSH-treated does exhibiting estrus (n=9) had a mean (*SE) of 10.111.7 corpora lutea (CL) and was significantly different (Pc.05) from the mean number of CL (1.4k.02) for control animals which ovulated during the trial (n=7). Superovulated does (n=7) had a mean of 6.Ok1.2 ova and 4.7k1.3 embryos recovered per collection. The inability to obtain ova from two donors and the low ova recovery rate were attributed to technician inexperience rather than the hormone treatment schedule. Of the 33 embryos (early morulae to expanded blastocysts) collected, 23 transferable-quality embryos were selected for freezing procedures and embryos of questionable quality were cultured in CMRL medium. In addition, four excellent quality embryos (late morulae and blastocysts) were split with a Leitz micromanipulator, and two halves were subsequently transferred to synchronized recipients with the aid of a Forty-five days following the laparoscopic embryo translaparoscope. fers, three of the four recipients (75%) were not detected in estrus These results demonstrate the sucand are assumed to be pregnant. cessful use of norgestomet implants and FSH in superovulation of does for embryo transfer.
Supported in part by funds Acknowledgement: Health Formula Funds, Section 1433, PL-95-113.
180
from
JANUARY
the
USDA
Animal
1986 VOL. 25 NO. 1
THE USE OF NORGESTOMET IMPLANTS AND FSH FOR ESTRUS SYNCHRONIZATION AND SUPEROVULATION IN GOATS R. J. Pendletonl, C. R. Youngsl, R. W. Roriel, M. A. Memon2 and R. A. Godkel 'Animal Science Department, LAES, LSU Agricultural Center 2Department of Veterinary Clinical Sciences, LSU School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803
The objective of this study was to assess the feasibilit of using norgestomet ear implants and follicle stimulating hormone rFSH) in a caprine embryo transfer program. In late June, ten crossbred dairy goats of varying ages were implagted with a standard bovine 6 mg norgestomet ear implant (Syncromate-B , CEVA Laboratories, Inc.) for 16 to 17 days. Implants were replaced with new implants after 10 days to insure an adequate progestagen treatment. Superovulation was induced by twice dail,y injections of descending doses of 4, 3, 2 and 1 mg of FSH (FSH-P :Burns-Biotec) starting 2 days prior to implant removal. Similarly, control does (n=lO) were administered saline (as a placebo) and were checked for signs of estrus with a vasectomized male along with the treated does. Starting at the onset of estrus, all treated does were naturally mated to several males each morning and evening until the end of estrus. After implant removal, 6 of 10 treated animals exhibited estrus within 24 hours and 9 of 10 within 48 hours. The remaining doe which failed to show estrus had exudate around the implant which likely impaired its effectiveness. Two of the control does exhibited estrus during the estrus detection period. Embryos were surgically collected on days 5 to 6 of the estrous cycle (day 0 = onset of estrus), and control does were laparoscopically examined at that time to evaluate ovarian activity. The FSH-treated does exhibiting estrus (n=9) had a mean (*SE) of 10.111.7 corpora lutea (CL) and was significantly different (Pc.05) from the mean number of CL (1.4k.02) for control animals which ovulated during the trial (n=7). Superovulated does (n=7) had a mean of 6.Ok1.2 ova and 4.7k1.3 embryos recovered per collection. The inability to obtain ova from two donors and the low ova recovery rate were attributed to technician inexperience rather than the hormone treatment schedule. Of the 33 embryos (early morulae to expanded blastocysts) collected, 23 transferable-quality embryos were selected for freezing procedures and embryos of questionable quality were cultured in CMRL medium. In addition, four excellent quality embryos (late morulae and blastocysts) were split with a Leitz micromanipulator, and two halves were subsequently transferred to synchronized recipients with the aid of a Forty-five days following the laparoscopic embryo translaparoscope. fers, three of the four recipients (75%) were not detected in estrus These results demonstrate the sucand are assumed to be pregnant. cessful use of norgestomet implants and FSH in superovulation of does for embryo transfer.
Supported in part by funds Acknowledgement: Health Formula Funds, Section 1433, PL-95-113.
180
from
JANUARY
the
USDA
Animal
1986 VOL. 25 NO. 1